EMRIS Pharma

EMRIS Pharma is revolutionizing cancer treatment with a mission to prevent and treat skin toxicities associated with targeted therapies. ​ Our primary groundbreaking therapy, a small molecule-based topical drug, is addressing the skin toxicities induced by EGFR inhibitors (EGFRi) monoclonal antibodies, which are used as a targeted treatment for advanced colorectal and head and neck cancers. A vast majority of patients (~90%) undergoing these treatments suffer from severe skin toxicities that impair their well-being. Current treatments and other new developments focus on symptom reduction post-EGFR inhibition and provide limited relief. The most effective treatment often involves dose reduction or interruptions in the anti-cancer drug protocol.​ ​ Our innovative approach blocks the initial trigger causing skin toxicity locally without interfering with the cancer treatment. This solution aims to significantly improve the quality of life for cancer patients and help them comply with their treatments.